150 related articles for article (PubMed ID: 16287063)
1. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia.
Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Garate L; Montiel-Duarte C; Artieda P; Cordeu L; Lahortiga I; Calasanz MJ; Heiniger A; Torres A; Minna JD; Prósper F
Int J Cancer; 2006 Apr; 118(8):1945-53. PubMed ID: 16287063
[TBL] [Abstract][Full Text] [Related]
2. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
3. PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome.
Toma MI; Wuttig D; Kaiser S; Herr A; Weber T; Zastrow S; Koch R; Meinhardt M; Baretton GB; Wirth MP; Fuessel S
Genes Chromosomes Cancer; 2013 Mar; 52(3):265-73. PubMed ID: 23125027
[TBL] [Abstract][Full Text] [Related]
4. Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Cai M; Tian J; Zhao GH; Luo W; Zhang BR
Int J Neurosci; 2011 Sep; 121(9):497-502. PubMed ID: 21663383
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance.
Narayan G; Freddy AJ; Xie D; Liyanage H; Clark L; Kisselev S; Un Kang J; Nandula SV; McGuinn C; Subramaniyam S; Alobeid B; Satwani P; Savage D; Bhagat G; Murty VV
Genes Chromosomes Cancer; 2011 Dec; 50(12):1043-53. PubMed ID: 21960365
[TBL] [Abstract][Full Text] [Related]
6. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer.
Denison SR; Callahan G; Becker NA; Phillips LA; Smith DI
Genes Chromosomes Cancer; 2003 Sep; 38(1):40-52. PubMed ID: 12874785
[TBL] [Abstract][Full Text] [Related]
7. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter.
San José-Enériz E; Agirre X; Román-Gómez J; Cordeu L; Garate L; Jiménez-Velasco A; Vázquez I; Calasanz MJ; Heiniger A; Torres A; Prósper F
Br J Haematol; 2006 Jul; 134(2):137-44. PubMed ID: 16846474
[TBL] [Abstract][Full Text] [Related]
9. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers.
Dunwell T; Hesson L; Rauch TA; Wang L; Clark RE; Dallol A; Gentle D; Catchpoole D; Maher ER; Pfeifer GP; Latif F
Mol Cancer; 2010 Feb; 9():44. PubMed ID: 20184741
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.
Ortmann CA; Burchert A; Hölzle K; Nitsche A; Wittig B; Neubauer A; Schmidt M
Nucleic Acids Res; 2005; 33(21):6895-905. PubMed ID: 16396836
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia.
Della Peruta M; Martinelli G; Moratti E; Pintani D; Vezzalini M; Mafficini A; Grafone T; Iacobucci I; Soverini S; Murineddu M; Vinante F; Tecchio C; Piras G; Gabbas A; Monne M; Sorio C
Cancer Res; 2010 Nov; 70(21):8896-906. PubMed ID: 20959494
[TBL] [Abstract][Full Text] [Related]
12. The dual role of HLXB9 in leukemia.
Ferguson S; Gautrey HE; Strathdee G
Pediatr Blood Cancer; 2011 Mar; 56(3):349-52. PubMed ID: 21069786
[TBL] [Abstract][Full Text] [Related]
13. The methylation status of the major breakpoint cluster region in human leukemia cells, including Philadelphia chromosome-positive cells, is linked to the lineage of hematopoietic cells.
Ohyashiki JH; Ohyashiki K; Kawakubo K; Tauchi T; Shimamoto T; Toyama K
Leukemia; 1993 Jun; 7(6):801-7. PubMed ID: 8501975
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
Ahuja H; Bar-Eli M; Arlin Z; Advani S; Allen SL; Goldman J; Snyder D; Foti A; Cline M
J Clin Invest; 1991 Jun; 87(6):2042-7. PubMed ID: 2040694
[TBL] [Abstract][Full Text] [Related]
15. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
16. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
[TBL] [Abstract][Full Text] [Related]
17. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
[TBL] [Abstract][Full Text] [Related]
18. Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism.
Lesage S; Magali P; Lohmann E; Lacomblez L; Teive H; Janin S; Cousin PY; Dürr A; Brice A;
Hum Mutat; 2007 Jan; 28(1):27-32. PubMed ID: 17068781
[TBL] [Abstract][Full Text] [Related]
19. The dioxin receptor is silenced by promoter hypermethylation in human acute lymphoblastic leukemia through inhibition of Sp1 binding.
Mulero-Navarro S; Carvajal-Gonzalez JM; Herranz M; Ballestar E; Fraga MF; Ropero S; Esteller M; Fernandez-Salguero PM
Carcinogenesis; 2006 May; 27(5):1099-104. PubMed ID: 16410262
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
